Matthew Buten Net Worth

The estimated Net Worth of Matthew Buten is at least $6.76 Million dollars as of 5 October 2023. Mr Buten owns over 22,727 units of Biohaven Ltd stock worth over $6,764,654 and over the last 3 years he sold BHVN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Buten BHVN stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Biohaven Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 22,727 units of BHVN stock worth $499,994 on 5 October 2023.

The largest trade he's ever made was buying 142,857 units of Biohaven Ltd stock on 25 October 2022 worth over $1,499,999. On average, Mr trades about 22,261 units every 80 days since 2021. As of 5 October 2023 he still owns at least 189,380 units of Biohaven Ltd stock.

You can see the complete history of Mr Buten stock trades at the bottom of the page.

Mr. Matthew Buten biography

Matthew Buten is the Chief Financial Officer at Biohaven Ltd.

What's Mr Buten's mailing address?

Matthew's mailing address filed with the SEC is C/O BIOHAVEN LTD., 215 CHURCH STREET, NEW HAVEN, CT, 06510.

Insiders trading at Biohaven Ltd

Over the last 7 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs, and Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.

What does Biohaven Ltd do?

Complete history of Mr Buten stock trades at Biohaven Ltd

Biohaven Ltd executives and stock owners

Biohaven Ltd executives and other stock owners filed with the SEC include:

• Vlad Coric,
  Chief Executive Officer, Director
• William Jones,
  Chief Commercial Officer, Migraine and Common Diseases
• Charles Conway,
  Chief Scientific Officer
• Kimberly Gentile,
  Senior Vice President - Clinical Operations
• James Engelhart,
  Chief Financial Officer, Treasurer
• Elyse Stock,
  Chief Medical Officer
• John Tilton,
  Chief Commercial Officer, Rare and Orphan Diseases
• Dr. Vladimir Coric M.D.,
  Chairman, CEO & Pres
• William Jones M.B.A.,
  Chief Commercial Officer of Migraine & Common Diseases
• Julia Gregory,
  Independent Director
• John Childs,
  Director
• Gregory Bailey,
  Director
• Dr. Elyse Stock M.D.,
  Chief Medical Officer
• Kimberly Gentile,
  Sr. VP of Clinical Operations
• Robert Berman,
  Lead - Special Projects and Medical Oversight
• Robert Hugin,
  Director
• Michael Heffernan,
  Director
• Thomas Lynch,
  Chairman of the Board
• Clifford Bechtold M.S.,
  Pres & GM of Biohaven Ireland and Chief Compliance Officer
• Wendy Goss,
  Exec. Admin. Assistant
• Dr. Charles Conway,
  Chief Scientific Officer
• George C. Clark,
  VP & Chief Accounting Officer
• Matthew DeLawder,
  Director of Accounting
• Matthew Buten,
  Chief Financial Officer
• Albert Cha,
  Director
• Robert Repella,
  Director
• Eric Aguiar,
  
• Biotech Inc. Portage,
  
• Declan Doogan,
  
• Irina Antonijevic,
  
• Kishan Mehta,
  
• George C. Clark,
  VP, Chief Accounting Officer
• Matthew Buten,
  Chief Financial Officer
• Pharmaceutical Holding Co L...,
  
• Bruce Car,
  Chief Scientific Officer